KIT-mutant inhibitor DCC-3009

{
  "id": "MLC-T-ONC-014646",
  "term": "KIT-mutant inhibitor DCC-3009",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable switch-control inhibitor of multiple mutated forms of mast/stem cell factor receptor KIT (c-Kit; SCFR), with potential antineoplastic activity. Upon oral administration, KIT-mutant inhibitor DCC-3009 targets and binds to the switch pocket of c-Kit, thereby inhibiting the activity of specific c-Kit mutants, including primary KIT mutations in exons 9 and 11 and secondary drug-resistant mutations across exons 13, 14, 17, and 18. This may inhibit tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase (RTK) overexpressed in various solid tumors and hematological malignancies, plays a key role in the regulation of cell differentiation and proliferation. Mutant forms of c-Kit are often associated with tumor chemoresistance.",
  "synonyms": [
    "c-KIT inhibitor DCC-3009",
    "pan-exon mutant KIT inhibitor DCC-3009"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/kit-mutant-inhibitor-dcc-3009/"
}